<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        12-174-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIS-TAC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CISATRACURIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Fresenius Kabi manufacturing SA (Pty) Ltd " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Fresenius Kabi manufacturing SA (Pty) Ltd 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Fresenius Kabi Deutschland GmbH 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M03AC11 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:7.2pt; margin-right:0cm">Cis-Tac belongs to a group of medicines called muscle relaxants.</p><p style="margin-left:7.2pt; margin-right:0cm">Cis-Tac is used:</p><p style="margin-left:43.2pt; margin-right:36.0pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->to relax muscles during a wide range of surgical procedures in adults and children over 1 month of age,</p><p style="margin-left:43.2pt; margin-right:18.0pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->to help insert a tube into the windpipe (tracheal intubation), if a person needs help to breathe,</p><p style="margin-left:43.2pt; margin-right:0cm; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->to relax the muscles of adults in intensive care.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:7.2pt; margin-right:21.6pt; text-align:justify"><strong>Cis-Tac must not be used if </strong>you are <strong>allergic </strong>to <strong>cisatracurium, atracurium </strong>or <strong>benzenesulfonic acid</strong>.</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Warnings and precautions</strong></p><p style="margin-left:7.2pt">Talk to your doctor, pharmacist or nurse before you are given, Cis-Tac if you have:</p><p style="margin-left:25.2pt; margin-right:43.2pt; text-indent:-18.0pt">-&nbsp;&nbsp;&nbsp; muscle weakness, tiredness or difficulty in co-ordination of your movements (myasthenia gravis),</p><p style="margin-left:7.2pt; margin-right:0cm">-&nbsp;&nbsp;&nbsp; a neuromuscular disease, such as a muscle wasting disease, paralysis, motor</p><p style="margin-left:25.2pt">neurone disease or cerebral palsy,</p><p style="margin-left:7.2pt; margin-right:0cm">- a burn which requires medical treatment,</p><p style="margin-left:7.2pt; margin-right:0cm">-&nbsp;&nbsp;&nbsp; a severe acid-base and/or electrolyte disorder,</p><p style="margin-left:25.2pt; margin-right:25.2pt; text-indent:-18.0pt">-&nbsp;&nbsp;&nbsp; ever had an allergic reaction to any muscle relaxant which was given as part of an operation.</p><p style="margin-left:7.2pt; margin-right:32.4pt">If you are not sure if any of the above applies to you, talk to your doctor, nurse or pharmacist before you are given Cis-Tac.</p><p>&nbsp;</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Children</strong></p><p style="margin-left:7.2pt; margin-right:0cm">Children under the age of one month (new-born infants) should not receive Cis-Tac.</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Other medicines and Cis-Tac.</strong></p><p style="margin-left:7.2pt; margin-right:7.2pt">Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is especially important with the following medicines as they may interact with your Cis-Tac:</p><p style="margin-left:7.2pt; margin-right:0cm">-&nbsp;&nbsp;&nbsp;&nbsp; anaesthetics (used for sedation and pain reduction during surgical procedures,</p><p style="margin-left:25.2pt">such as enflurane, isoflurane, halothane, ketamine)</p><p style="margin-left:7.2pt; margin-right:0cm">- other muscle relaxants, such as suxamethonium</p><p style="margin-left:7.2pt">- antibiotics (used to treat infections, such as aminoglycosides, polymyxins,</p><p style="margin-left:25.2pt">spectinomycin, tetracyclines, lincomycin and clindamycin)</p><p style="margin-left:7.2pt; margin-right:0cm">- antiarrhythmics (used to control the heart rhythm, such as propranolol, oxprenolol,</p><p style="margin-left:25.2pt">calcium channel blockers, lidocaine, procainamide and quinidine)</p><p style="margin-left:25.2pt; margin-right:93.6pt; text-indent:-18.0pt">-&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat high blood pressure, such as trimethaphan and hexamethonium</p><p style="margin-left:25.2pt; margin-right:82.8pt; text-indent:-18.0pt">-&nbsp;&nbsp;&nbsp;&nbsp; diuretics (water tablets, such as furosemide, thiazides, mannitol and acetazolamide)</p><p style="margin-left:7.2pt; margin-right:72.0pt">-&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat rheumatism, such as chloroquine or d-penicillamine - steroids</p><p style="margin-left:7.2pt">-&nbsp;&nbsp;&nbsp;&nbsp; anti-epileptic medicines, such as phenytoin or carbamazepine</p><p style="margin-left:7.2pt; margin-right:82.8pt">-&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat mental illness, such as lithium, or chlorpromazine - medicines containing magnesium</p><p style="margin-left:7.2pt">-&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat Alzheimer&rsquo;s disease (anticholinesterases e.g. donepezil)</p><p style="margin-left:7.2pt; margin-right:7.2pt">It may still be all right for you to receive Cis-Tac and your doctor will be able to decide what is suitable for you.</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Pregnancy, breast-feeding and fertility</strong></p><p style="margin-left:7.2pt; margin-right:7.2pt">There is little experience in the use of Cis-Tac in pregnant or breast-feeding women. Therefore, it is not recommended to use Cis-Tac during pregnancy or breast-feeding. An influence on the suckling child is not to be expected if you restart breast-feeding after the effects of the substance have worn off. As a precaution breast-feeding should be discontinued during treatment and for at least 12 hours after administration of Cis-Tac.</p><p style="margin-left:7.2pt; margin-right:7.2pt">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby ask your doctor or pharmacist for advice before this medicine is given to you.</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Driving and using machines</strong></p><p style="margin-left:7.2pt; margin-right:18.0pt">Cis-Tac is administered under general anaesthesia. General anaesthesia has a major influence on your ability to drive and use machinery. It can be dangerous to drive, operate machinery or work in dangerous situations too soon after having had an operation.</p><p style="margin-left:7.2pt; margin-right:0cm">Your doctor will tell you when you can start driving and using machinery again.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:7.2pt; margin-right:0cm"><strong>How your injection is given</strong></p><p>&nbsp;</p><p style="margin-left:7.2pt; margin-right:21.6pt">Cis-Tac must only be given to you by or under the supervision of an experienced doctor who is familiar with the use and action of this type of medicine. It will always be given under carefully controlled conditions, where emergency equipment is available.</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Dosage</strong></p><p style="margin-left:7.2pt; margin-right:0cm">Your doctor will decide on the dose of Cisatracurium you will be given.</p><p style="margin-left:7.2pt">The amount of Cis-Tac you need depends on:</p><p style="margin-left:43.2pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->your body weight</p><p style="margin-left:43.2pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->the amount and duration of muscle relaxation required</p><p style="margin-left:43.2pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->your expected response to the medicine</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Method of administration </strong><br />Cis-Tac will be given to you</p><p style="margin-left:43.2pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->as a single injection into your vein (intravenous bolus injection),</p><p style="margin-left:43.2pt; margin-right:36.0pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->as a continuous infusion into your vein (intravenous infusion or &ldquo;drip&rdquo;). This is where the drug is slowly given to you over a longer period of time.</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>If you receive more Cis-Tac than you should</strong></p><p style="margin-left:7.2pt; margin-right:0cm">As Cis-Tac will always be given to you under carefully controlled conditions, it is</p><p style="margin-left:7.2pt; margin-right:0cm">unlikely that you will be given too much.</p><p style="margin-left:7.2pt; margin-right:7.2pt">If you have received too much, or if it is suspected, that you may have received too much, appropriate action will be taken promptly by your doctor.</p><p style="margin-left:7.2pt; margin-right:7.2pt">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:7.2pt; margin-right:10.8pt">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="margin-left:7.2pt; margin-right:21.6pt">As all muscle relaxants cisatracurium can cause <strong>allergic reactions </strong>although serious allergic reactions are very rare (may affect up to 1 in 10,000 people ). Any sudden wheeziness, difficulty in breathing, swelling of the eyelids, face or lips and rash or itching (especially affecting your whole body) should be reported to a doctor immediately.</p><p style="margin-left:7.2pt; margin-right:0cm">The following side effects have been reported:</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Common (may affect up to 1 in 10 people)</strong></p><p style="margin-left:7.2pt; margin-right:0cm">- decrease in heart rate</p><p style="margin-left:7.2pt; margin-right:0cm">- decrease in blood pressure</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p style="margin-left:7.2pt">-&nbsp;&nbsp;&nbsp;&nbsp; a rash or redness of your skin</p><p style="margin-left:7.2pt">- bronchospasm (asthma-like symptoms)</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Very rare (may affect up to 1 in 10,000 people)</strong></p><p>&nbsp;</p><p style="margin-left:7.2pt; margin-right:0cm">-&nbsp;&nbsp;&nbsp;&nbsp; muscles weakness or failure</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:7.2pt; margin-right:0cm">Keep this medicine out of the sight and reach of children.</p><p style="margin-left:7.2pt; margin-right:10.8pt">Do not use this medicine after the expiry date which is stated on the carton and label after &ldquo;Exp.&rdquo;. The expiry date refers to the last day of that month.</p><p style="margin-left:7.2pt; margin-right:0cm"><strong>Storage conditions</strong></p><p style="margin-left:7.2pt; margin-right:0cm">Before opening: Store in a refrigerator (2 &ordm;C and 8 &deg;C).</p><p style="margin-left:7.2pt; margin-right:0cm">Do not freeze.</p><p style="margin-left:7.2pt">Keep the ampoules in the outer carton in order to protect from light.</p><p style="margin-left:7.2pt; margin-right:0cm">After opening and/or after dilution</p><p style="margin-left:7.2pt">For single use only.</p><p style="margin-left:7.2pt; margin-right:0cm">Cis-Tac should be used immediately after opening and/or dilution. Any unused</p><p style="margin-left:7.2pt">solution should be discarded.</p><p style="margin-left:7.2pt; margin-right:0cm">Do not use this medicine if you notice the solution is not clear and free of particles</p><p style="margin-left:7.2pt; margin-right:0cm">or if the container is damaged.</p><p style="margin-left:7.2pt; margin-right:10.8pt">Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:7.2pt; margin-right:0cm">The <strong>active substance </strong>is cisatracurium.</p><p style="margin-left:7.2pt">1 ml of Cis-Tac contains 2.68 mg cisatracurium besilate, equivalent to 2 mg</p><p style="margin-left:7.2pt; margin-right:0cm">cisatracurium.</p><p style="margin-left:7.2pt; margin-right:0cm">The <strong>other ingredients </strong>are benzenesulfonic acid 1% and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cis-Tac is a clear, colourless to pale yellow or greenish yellow solution for
injection/infusion.
Cis-Tac is available in packs of: 1 (5, 10, 50) clear glass ampoule(s), each containing 2.5 ml, 5 ml or 10 ml of solution.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:7.2pt; margin-right:0cm"><strong>Marketing Authorisation Holder </strong><br />Fresenius Kabi Deutschland GmbH<br />D-61346 Bad Homburg v.d.H<br />Germany</p><p>&nbsp;</p><p style="margin-left:3.6pt; margin-right:0cm"><strong>Manufacturer</strong></p><p style="margin-left:3.6pt; margin-right:0cm">Fresenius Kabi Manufacturing SA (Pty) Ltd</p><p style="margin-left:3.6pt">6 Gibaud Road,</p><p style="margin-left:3.6pt; margin-right:0cm">6001 Korsten,</p><p style="margin-left:3.6pt">Port Elizabeth</p><p>South Africa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:right">سيس-تاك ينتمي إلى مجموعه من الأدوية التي تسمي الاسترخاء العضلات. ويستخدم سيس-تاك:</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لاسترخاء العضلات خلال أنواع عدة من العمليات الجراحية في البالغين والأطفال بعمر أكثر من شهر واحد</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->للمساعدة في إدخال أنبوب في القصبة الهوائية (التنبيب الرغامي)، إذا كان الشخص يحتاج للمساعدة على التنفس</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لاسترخاء عضلات البالغين في قسم الرعاية الفائقة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>يجب ألا يستخدم سيس-تاك إذا كانت لديك حساسية من سيس أتراكوريوم، أتراكوريوم أو حامض البنزين سلفونيك</strong><strong>.</strong></p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>المحاذير والاحتياطات</strong><strong> </strong></p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تحدث إلى طبيبك، الصيدلي أو الممرضة قبل ان تعطي سيس-تاك إذا كان لديك:</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضعف أو تعب العضلات، أو صعوبة في اتساق الحركات (الوهن العضلي الوبيل)</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الامراض العصبية العضلية، مثل مرض هزال العضلات، الشلل، الأمراض العصبية الحركية أو الشلل دماغي</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الحرق الذي يتطلب علاجَا طبياً</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->اضطرابات شديده في التوازن الحمضي قاعدي و/أو الإلكتروليتيات</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تعرضت في اي وقت مضي لرد فعل تحسسي لأي من عقاقير استرخاء العضلات التي تعاطيتها أثناء أجراء عملية</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">إذا لم تكن متأكدا مما إذا كان أي مما سبق ينطبق عليك تحدث إلى طبيبك، الممرضة أو الصيدلي قبل ان تعطي سيس-تاك.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>الأطفال</strong></p><p dir="RTL" style="text-align:right">لا ينبغي ان يتلقى الأطفال الذين تقل أعمارهم عن شهر واحد (الرضع المولودون حديثا) سيس-تاك.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>الأدوية الأخرى وسيس-تاك</strong></p><p dir="RTL" style="text-align:right">أخبر طبيبك، الصيدلي أو الممرضة إذا كنت تتناول أو تناولت أو تزمع أن تتناول أي أدوية أخرى، هذا مهم بشكل خاص مع الأدوية التالية لأنها قد تتفاعل مع سيس-تاك:</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->العقاقير الخاصة بالتخدير (تستخدم في التخدير والحد من الألم أثناء الإجراءات الجراحية، مثل إنفلورين، أيزو فلورين، هلوثان، كتامين)</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مرخيات العضلات الأخرى، مثل سوكساميثنيوم</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المضادات الحيوية (المستخدمة لعلاج العدوى، مثل امينوجليكوسيدات، البوليميكسينات، بكتينوميسين، التيتراسيكلينات، لينكوميسين، كليداميسين)</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مضادات عدم الانتظام (المستخدمة للتحكم في إيقاع القلب، مثل البروبرانلوول، وأوكسي برينولول، وحاصرات قنوات الكالسيوم، وليدوكين، والبروسيناميد، والكينيدين)</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->أدوية علاج ارتفاع ضغط الدم، مثل تريميثافان وهيكساميثونيوم</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مدرات البول (اقراص الماء، مثل الفوروسيميد والثيازيدات والماننيتول والاسيتاززولاميد)</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->أدويه علاج الروماتيزم، مثل الكلوروكين أو d-بينيكيلامين</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الستيرويدات</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->أدوية علاج الصرع، مثل الفينيتوين أو كاربامازيبين</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->أدويه علاج الأمراض العقلية، مثل الليثيوم، أو الكلورو برومازين</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الأدوية التي تحتوي على المغنيسيوم</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->أدويه علاج مرض الزهايمر (الانزيمات المضادة للكولين إستريز مثل الدونيبيزيل)</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">قد يكون كل شيء ما زال على ما يرام لتتلقي سيس-تاك وسوف يكون طبيبك قادرا على تحديد ما هو مناسب لك.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL" style="text-align:right">لا توجد خبره تذكر في استخدام سيس-تاك في النساء الحوامل أو المرضعات.</p><p dir="RTL" style="text-align:right">ولذلك، لا ينصح باستخدام سيس-تاك اثناء الحمل أو الرضاعة الطبيعية. ليس من المتوقع التأثير علي الطفل الرضيع إذا عدتي للرضاعة الطبيعية بعد اختفاء اثار المادة. كإجراء وقائي ينبغي إيقاف الرضاعة الطبيعية اثناء العلاج ولمده 12 ساعة على الأقل بعد تعاطي سيس-تاك.</p><p dir="RTL" style="text-align:right">إذا كنت حاملا أو مرضعة، تعتقدين بأنك قد تكوني حاملا أو تخططين للحمل، اطلبي من طبيبك تقديم المشورة قبل إعطاءك الدواء.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL" style="text-align:right">سيس-تاك يعطى تحت التخدير العام. التخدير العام له تأثير كبير على قدرتك على القيادة واستخدام الآلات. يمكن ان يكون خطيرا أن تقوم بالقيادة، أو تشغيل الآلات أو العمل في ظروف خطره في وقت قريب جدا من انتهاء العملية.</p><p dir="RTL" style="text-align:right">طبيبك سوف يخبرك عن الوقت الذي تستطيع فيه البدء في القيادة واستخدام الآلات مره أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>كيف يتم إعطائك الحقنة</strong></p><p dir="RTL" style="text-align:right">سيس-تاك يجب ان يعطي لك من قبل أو تحت اشراف طبيب من ذوي الخبرة والدراية باستخدام وفاعلية هذا النوع من العقاقير. سيتم ذلك دائما في ظل ظروف تخضع لمراقبه دقيقه، حيث تتوفر معدات الطوارئ.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>الجرعة</strong></p><p dir="RTL" style="text-align:right">سيقرر طبيبك بشأن جرعه سيس أتراكوريوم التي ستعطي لك</p><p dir="RTL" style="text-align:right">كمية سيس-تاك التي تحتاجها تعتمد علي:</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وزن جسمك</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الكمية والمدة المطلوبة لاسترخاء العضلات</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الاستجابة المتوقعة للعقار</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>طريقه الإعطاء</strong></p><p dir="RTL" style="text-align:right">سيس-تاك سيعطي لك:</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->كحقنه واحده في الوريد (الحقن الوريدي بلعة واحدة)،</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->كضخ مستمر في الوريد (الضخ الوريدي أو &quot;التنقيط/التسريب&quot;). ويكون ذلك عندما يعطي لك العقار ببطء على مدي فتره طويلة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>إذا تعاطيت سيس-تاك أكثر مما يجب</strong></p><p dir="RTL" style="text-align:right">لأن سيس-تاك سيعطي لك دائما في ظل ظروف خاضعه للرقابة بعناية، فانه من غير المرجح ان تعطي أكثر مما يجب.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">إذا كنت قد تلقيت أكثر مما يجب، أو إذا كان يشتبه في أنك قد تلقيت أكثر مما يجب، سيتم اتخاذ الإجراءات المناسبة على الفور من قبل طبيبك.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">إذا كان لديك اي أسئلة أخرى حول استخدام هذا الدواء، أسال طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، وإن لم يكن كل شخص يحصل عليها.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">ككل مرخيات العضلات سيس أتراكوريوم يمكن ان يسبب <strong>ردود الفعل التحسسية</strong> على الرغم من أن ردود الفعل التحسسية الخطيرة نادره جدا (قد يؤثر على ما يصل إلى 1 من 10,000 شخص). اي صفير مفاجئ أثناء التنفس، أو صعوبة في التنفس، تورم في الجفون، الوجه أو الشفاه أو الطفح أو الحكة (التي تؤثر بشكل خاص على كامل الجسم) ينبغي ان تبلغ الطبيب علي الفور.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">تم رصد التأثيرات الجانبية التالية:</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>شائعة (قد تؤثر على ما يصل إلى 1 من 10 أشخاص)</strong></p><p dir="RTL" style="text-align:right">انخفاض في معدل ضربات القلب</p><p dir="RTL" style="text-align:right">انخفاض في ضغط الدم</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>غير شائعة (قد تؤثر على ما يصل إلى 1 من 100 شخص)</strong></p><p dir="RTL" style="text-align:right">طفح جلدي أو احمرار في الجلد</p><p dir="RTL" style="text-align:right">انقباض القصبات الهوائية (اعراض مثل الربو)</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>نادره جدا (قد تؤثر على ما يصل إلى 1 من 10,000 شخص)</strong></p><p dir="RTL" style="text-align:right">ضعف أو فشل العضلات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">احتفظ بهذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">لا تستخدم هذا الدواء بعد تاريخ الانتهاء المذكور علي الكرتون والذي يرد على الملصق بعد EXP. ويشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>شروط التخزين</strong></p><p dir="RTL" style="text-align:right">قبل الفتح: يخزن في الثلاجة (2 درجه مئوية إلى 8 درجات مئوية). لا تجمد.</p><p dir="RTL" style="text-align:right">يجب إبقاء الأمبولات في الكرتون الخارجي للحماية من الضوء.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">بعد الفتح و/أو بعد التمييع</p><p dir="RTL" style="text-align:right">للاستخدام مرة واحدة فقط.</p><p dir="RTL" style="text-align:right">سيس-تاك يجب ان يستخدم مباشره بعد الفتح و/أو التمييع. يجب التخلص من اي محلول غير مستخدم.</p><p dir="RTL" style="text-align:right">لا تستخدم هذا الدواء إذا لاحظت ان المحلول غير نقي وخالي من العوالق أو إذا كانت الحاوية معطوبة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">لا تتخلص من اي ادويه عن طريق مياه الصرف. أطلب من الصيدلي التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL" style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>ما يحتوي عليه سيس-تاك</strong><strong> </strong></p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">&nbsp;<strong>المادة الفعالة</strong> هو سيس أتراكوريوم.</p><p dir="RTL" style="text-align:right">1 مل من سيس-تاك يحتوي علي 2.68 ملغ سيس أتراكوريوم بيسايلات، اي ما يعادل 2 ملغ سيس أتراكوريوم.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">&nbsp;<strong>المكونات الأخرى</strong> 1% حامض البنزين سلفونيك، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>كيف يبدو سيس-تاك وما هي محتويات العبوة</strong><strong> </strong></p><p dir="RTL" style="text-align:right">سيس-تاك هو محلول شفاف واضح، بلا لون أو يميل للأصفر الباهت أو الأصفر المخضر للحقن/التسريب/الضخ.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">سيس-تاك يتوفر في عبوات: 1 (5، 10، 50) أمبولة زجاجية شفافة، تحتوي كل منها على 2.5 مل، أو 5 مل أو 10 مل من المحلول.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>ترخيص التسويق والمصنّع</strong><strong> </strong></p><p dir="RTL" style="text-align:right">فريزنيوس كابي دويتشلاند جي ام بي إتش D-61346 باد همبورغ في دي إتش ألمانيا</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>المصنع</strong></p><p dir="RTL" style="text-align:right">فريزنيوس كابي مانيوفكشرينج &ndash; أس أيه</p><p dir="RTL" style="text-align:right">6 جيبود رود,</p><p dir="RTL" style="text-align:right">6001 كورستن، بورت اليزابيث</p><p dir="RTL" style="text-align:right">جنوب افريقيا</p><p dir="RTL" style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cis-Tac 2 mg/ml solution for injection/infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml solution for injection/infusion contains 2.68 mg cisatracurium besilate equivalent to 2 mg cisatracurium.
1 ampoule of 2.5 ml solution for injection/infusion contains 6.7 mg cisatracurium besilate
equivalent to 5 mg cisatracurium.
1 ampoule of 5 ml solution for injection/infusion contains 13.4 mg cisatracurium besilate
equivalent to 10 mg cisatracurium.
1 ampoule of 10 ml solution for injection/infusion contains 26.8 mg cisatracurium besilate
equivalent to 20 mg cisatracurium.
For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection/infusion (injection/infusion)
Clear, colourless to pale yellow or greenish yellow solution with a pH of 3.0 - 3.8.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Cis-Tac is indicated for use during surgical and other procedures in adults and children aged 1 month and over. Cis-Tac is also indicated for use in adults requiring intensive care. Cis-Tac can be used as an adjunct to general anaesthesia, or sedation in the Intensive Care Unit (ICU) to relax skeletal muscles, and to facilitate endotracheal intubation and mechanical ventilation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Cis-Tac should only be administered by or under the supervision of anaesthetists or other clinicians who are familiar with the use and action of neuromuscular blocking agents. Facilities for tracheal intubation and maintenance of pulmonary ventilation and adequate arterial oxygenation have to be available.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Monitoring of neuromuscular function is recommended during the use of Cis-Tac in order to individualise dosage requirements.</p><p style="margin-left:36.0pt; margin-right:0cm"><strong><u>Posology</u></strong><strong> </strong></p><p style="margin-left:36.0pt; margin-right:0cm"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use by intravenous bolus injection</strong></p><p style="margin-left:36.0pt; margin-right:0cm"><strong><em>Dosage in adults</em></strong></p><p style="margin-left:36.0pt; margin-right:0cm"><u>Endotracheal Intubation </u></p><p style="margin-right:10.8pt">The recommended intubation dose of cisatracurium for adults is 0.15 mg/kg (body weight). Endotracheal intubation can be accomplished 120 seconds after administration of Cis-Tac, following induction of anaesthesia with propofol.</p><p>Higher doses will shorten the time to onset of neuromuscular block.</p><p style="margin-left:0cm; margin-right:10.8pt">The following table summarises mean pharmacodynamic data when cisatracurium was administered at doses of 0.1 to 0.4 mg/kg (body weight) to healthy adult patients during opioid (thiopentone/fentanyl/midazolam) or propofol anaesthesia.</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:57.35pt; vertical-align:top; width:90.0pt"><p style="margin-left:3.6pt; margin-right:0cm">Initial</p><p style="margin-left:3.6pt; margin-right:0cm">cisatracurium dose (mg/kg bw)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:80.4pt"><p style="margin-left:1.8pt; margin-right:0cm">Anaesthetic Background</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:84.25pt"><p style="margin-left:3.6pt; margin-right:7.2pt">Time to 90% T1* Suppression (min)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:84.0pt"><p style="margin-left:3.6pt; margin-right:16.2pt">Time to Maximum T1* Suppression (min)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:75.35pt"><p style="margin-left:3.6pt; margin-right:0cm">Time to 25% Spontaneous T1*Recovery (min)</p></td></tr><tr><td style="border-color:black; height:19.2pt; width:90.0pt"><p style="margin-left:0cm; margin-right:0cm">0.1</p></td><td style="height:19.2pt; width:80.4pt"><p style="margin-left:3.35pt; margin-right:0cm">Opioid</p></td><td style="height:19.2pt; width:84.25pt"><p style="margin-left:0cm; margin-right:0cm">3.4</p></td><td style="height:19.2pt; width:84.0pt"><p style="margin-left:0cm; margin-right:0cm">4.8</p></td><td style="height:19.2pt; width:75.35pt"><p style="margin-left:3.1pt; margin-right:0cm">45</p></td></tr><tr><td style="border-color:black; height:19.2pt; width:90.0pt"><p style="margin-left:0cm; margin-right:0cm">0.15</p></td><td style="height:19.2pt; width:80.4pt"><p style="margin-left:3.35pt; margin-right:0cm">Propofol</p></td><td style="height:19.2pt; width:84.25pt"><p style="margin-left:0cm; margin-right:0cm">2.6</p></td><td style="height:19.2pt; width:84.0pt"><p style="margin-left:0cm; margin-right:0cm">3.5</p></td><td style="height:19.2pt; width:75.35pt"><p style="margin-left:3.1pt; margin-right:0cm">55</p></td></tr><tr><td style="border-color:black; height:19.2pt; width:90.0pt"><p style="margin-left:0cm; margin-right:0cm">0.2</p></td><td style="height:19.2pt; width:80.4pt"><p style="margin-left:3.35pt; margin-right:0cm">Opioid</p></td><td style="height:19.2pt; width:84.25pt"><p style="margin-left:0cm; margin-right:0cm">2.4</p></td><td style="height:19.2pt; width:84.0pt"><p style="margin-left:0cm; margin-right:0cm">2.9</p></td><td style="height:19.2pt; width:75.35pt"><p style="margin-left:3.1pt; margin-right:0cm">65</p></td></tr><tr><td style="border-color:black; height:19.45pt; width:90.0pt"><p style="margin-left:0cm; margin-right:0cm">0.4</p></td><td style="height:19.45pt; width:80.4pt"><p style="margin-left:3.35pt; margin-right:0cm">Opioid</p></td><td style="height:19.45pt; width:84.25pt"><p style="margin-left:0cm; margin-right:0cm">1.5</p></td><td style="height:19.45pt; width:84.0pt"><p style="margin-left:0cm; margin-right:0cm">1.9</p></td><td style="height:19.45pt; width:75.35pt"><p style="margin-left:3.1pt; margin-right:0cm">91</p></td></tr></tbody></table><p style="margin-right:10.8pt; text-align:justify">* T1 Single twitch response as well as the first component of the Train-of-four response of the adductor pollicis muscle following supramaximal electrical stimulation of the ulnar nerve.</p><p style="margin-left:0cm; margin-right:10.8pt; text-align:justify">Enflurane or isoflurane anaesthesia may extend the clinically effective duration of an initial dose of cisatracurium by up to 15%.</p><p><u>Maintenance </u>&nbsp;</p><p style="margin-right:10.8pt; text-align:justify">Neuromuscular block can be extended with maintenance doses of cisatracurium. A dose of 0.03 mg/kg (body weight) provides approximately 20 minutes of additional clinically effective neuromuscular block during opioid or propofol anaesthesia.</p><p style="margin-right:10.8pt; text-align:justify">Successive supplementary dosing does not produce accumulation in neuromuscular blocking effect.</p><p><u>Spontaneous Recovery </u></p><p style="margin-right:10.8pt; text-align:justify">Once evidence of spontaneous recovery from neuromuscular block is present, the duration until complete reversal is independent of the cisatracurium dose administered. During opioid or propofol anaesthesia, the mean duration for recovery from 25 to 75% and from 5 to 95% is approximately 13 and 30 minutes, respectively.</p><p><u>Reversal </u>&nbsp;</p><p style="margin-right:10.8pt; text-align:justify">Neuromuscular block following cisatracurium administration is readily reversible with standard doses of anticholinesterase agents. The mean duration of recovery from 25 to 75% and to full clinical recovery (T4:T1 ratio &ge; 0.7) is approximately 4 and 9 minutes, respectively, following administration of the reversal agent at an average T1 recovery of 10%.</p><p><strong><em>Dosage in paediatric population</em></strong></p><p><u>Endotracheal Intubation (paediatric patients aged 1 month to 12 years) </u></p><p>As in adults, the recommended intubation dose of cisatracurium is 0.15 mg/kg (body weight)</p><p>administered rapidly over 5 to 10 seconds. Endotracheal intubation can be accomplished 120</p><p>seconds after administration of cisatracurium.</p><p>Pharmacodynamic data for this dose are presented in the tables below.</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">Cisatracurium has not been studied for intubation in ASA Class III-IV paediatric patients. There are limited data on the use of cisatracurium in paediatric patients under 2 years of age undergoing prolonged or major surgery.</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">In paediatric patients aged 1 month to 12 years, cisatracurium has a shorter clinically effective duration and a faster spontaneous recovery profile than those observed in adults under similar anaesthetic conditions. Small differences in the pharmacodynamic profile were observed between the age ranges 1 to 11 months and 1 to 12 years which are summarised in the tables below.</p><p style="margin-left:3.6pt; margin-right:0cm">Paediatric Patients aged 1 to 11 months</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:57.35pt; vertical-align:top; width:92.15pt"><p style="margin-left:3.6pt; margin-right:7.2pt">Cisatracurium Dose mg/kg (body weight)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:83.75pt"><p style="margin-left:1.8pt; margin-right:0cm">Anaesthetic Background</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:84.0pt"><p style="margin-left:3.6pt; margin-right:0cm">Time to 90%<br />Suppression<br />(min)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:83.8pt"><p style="margin-left:3.6pt; margin-right:0cm">Time to<br />Maximum<br />Suppression<br />(min)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:83.75pt"><p style="margin-left:1.8pt; margin-right:0cm">Time to 25% Spontaneous T1 Recovery (min)</p></td></tr><tr><td style="border-color:black; height:19.2pt; width:92.15pt"><p style="margin-left:3.35pt; margin-right:0cm">0.15</p></td><td style="height:19.2pt; width:83.75pt"><p style="margin-left:3.35pt; margin-right:0cm">Halothane</p></td><td style="height:19.2pt; width:84.0pt"><p style="margin-left:3.6pt; margin-right:0cm">1.4</p></td><td style="height:19.2pt; width:83.8pt"><p style="margin-left:3.15pt; margin-right:0cm">2.0</p></td><td style="height:19.2pt; width:83.75pt"><p style="margin-left:3.1pt; margin-right:0cm">52</p></td></tr><tr><td style="border-color:black; height:19.45pt; width:92.15pt"><p style="margin-left:3.35pt; margin-right:0cm">0.15</p></td><td style="height:19.45pt; width:83.75pt"><p style="margin-left:3.35pt; margin-right:0cm">Opioid</p></td><td style="height:19.45pt; width:84.0pt"><p style="margin-left:3.6pt; margin-right:0cm">1.4</p></td><td style="height:19.45pt; width:83.8pt"><p style="margin-left:3.15pt; margin-right:0cm">1.9</p></td><td style="height:19.45pt; width:83.75pt"><p style="margin-left:3.1pt; margin-right:0cm">47</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:3.6pt; margin-right:0cm">Paediatric Patients aged 1 to 12 years</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:57.35pt; vertical-align:top; width:92.15pt"><p style="margin-left:3.6pt; margin-right:7.2pt">Cisatracurium Dose mg/kg (body weight)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:83.75pt"><p style="margin-left:1.8pt; margin-right:0cm">Anaesthetic Background</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:84.0pt"><p style="margin-left:3.6pt; margin-right:0cm">Time to 90%<br />Suppression<br />(min)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:83.8pt"><p style="margin-left:3.6pt; margin-right:0cm">Time to<br />Maximum<br />Suppression<br />(min)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:83.75pt"><p style="margin-left:1.8pt; margin-right:0cm">Time to 25% Spontaneous T1 Recovery (min)</p></td></tr><tr><td style="border-color:black; height:19.2pt; width:92.15pt"><p style="margin-left:3.35pt; margin-right:0cm">0.15</p></td><td style="height:19.2pt; width:83.75pt"><p style="margin-left:3.35pt; margin-right:0cm">Halothane</p></td><td style="height:19.2pt; width:84.0pt"><p style="margin-left:3.35pt; margin-right:0cm">2.3</p></td><td style="height:19.2pt; width:83.8pt"><p style="margin-left:3.15pt; margin-right:0cm">3.0</p></td><td style="height:19.2pt; width:83.75pt"><p style="margin-left:3.1pt; margin-right:0cm">43</p></td></tr><tr><td style="border-color:black; height:19.45pt; width:92.15pt"><p style="margin-left:3.35pt; margin-right:0cm">0.15</p></td><td style="height:19.45pt; width:83.75pt"><p style="margin-left:3.35pt; margin-right:0cm">Opioid</p></td><td style="height:19.45pt; width:84.0pt"><p style="margin-left:3.35pt; margin-right:0cm">2.6</p></td><td style="height:19.45pt; width:83.8pt"><p style="margin-left:3.15pt; margin-right:0cm">3.6</p></td><td style="height:19.45pt; width:83.75pt"><p style="margin-left:3.1pt; margin-right:0cm">38</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">When cisatracurium is not required for intubation: A dose of less than 0.15 mg/kg can be used. Pharmacodynamic data for doses of 0.08 and 0.1 mg/kg for paediatric patients aged 2 to 12 years are presented in the table below:</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:57.35pt; vertical-align:top; width:92.15pt"><p style="margin-left:3.6pt; margin-right:7.2pt">Cisatracurium Dose mg/kg (body weight)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:83.75pt"><p style="margin-left:1.8pt; margin-right:0cm">Anaesthetic Background</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:84.0pt"><p style="margin-left:3.6pt; margin-right:0cm">Time to 90%<br />Suppression<br />(min)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:83.8pt"><p style="margin-left:3.6pt; margin-right:0cm">Time to<br />Maximum<br />Suppression<br />(min)</p></td><td style="border-color:black; height:57.35pt; vertical-align:top; width:83.75pt"><p style="margin-left:1.8pt; margin-right:0cm">Time to 25% Spontaneous T1 Recovery (min)</p></td></tr><tr><td style="border-color:black; height:19.2pt; width:92.15pt"><p style="margin-left:3.35pt; margin-right:0cm">0.08</p></td><td style="height:19.2pt; width:83.75pt"><p style="margin-left:3.35pt; margin-right:0cm">Halothane</p></td><td style="height:19.2pt; width:84.0pt"><p style="margin-left:3.6pt; margin-right:0cm">1.7</p></td><td style="height:19.2pt; width:83.8pt"><p style="margin-left:3.15pt; margin-right:0cm">2.5</p></td><td style="height:19.2pt; width:83.75pt"><p style="margin-left:3.1pt; margin-right:0cm">31</p></td></tr><tr><td style="border-color:black; height:19.7pt; width:92.15pt"><p style="margin-left:3.35pt; margin-right:0cm">0.1</p></td><td style="height:19.7pt; width:83.75pt"><p style="margin-left:3.35pt; margin-right:0cm">Opioid</p></td><td style="height:19.7pt; width:84.0pt"><p style="margin-left:3.6pt; margin-right:0cm">1.7</p></td><td style="height:19.7pt; width:83.8pt"><p style="margin-left:3.15pt; margin-right:0cm">2.8</p></td><td style="height:19.7pt; width:83.75pt"><p style="margin-left:3.1pt; margin-right:0cm">28</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:3.6pt; margin-right:18.0pt">Administration of cisatracurium following suxamethonium has not been studied in paediatric patients (see section 4.5).</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">Halothane may extend the clinically effective duration of a dose of cisatracurium by up to 20%.</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">No information is available on the use of cisatracurium in children during anaesthesia with other halogenated fluorocarbon anaesthetic agents. Nevertheless, these agents may also be expected to extend the clinically effective duration of a cisatracurium dose.</p><p style="margin-left:3.6pt; margin-right:0cm"><u>Maintenance (paediatric patients aged 2-12 years) </u></p><p style="margin-left:3.6pt; margin-right:7.2pt">Neuromuscular block can be extended with maintenance doses of cisatracurium. In paediatric patients aged 2 to 12 years, a dose of 0.02 mg/kg (body weight) provides approximately 9 minutes of additional clinically effective neuromuscular block during halothane anaesthesia. Successive supplementary dosing does not produce accumulation in neuromuscular blocking effect.</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">There are insufficient data available for recommendation of maintenance dosing in paediatric patients under 2 years of age. However, very limited data from clinical studies in paediatric patients under 2 years of age suggest that a maintenance dose of 0.03 mg/kg may extend clinically effective neuromuscular block for a period of up to 25 minutes during opioid anaesthesia.</p><p style="margin-left:3.6pt; margin-right:0cm"><u>Spontaneous Recovery </u></p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">Once evidence of spontaneous recovery from neuromuscular block is present, the duration until complete reversal is independent of the cisatracurium dose administered. During opioid or halothane anaesthesia, the mean duration for recovery from 25 to 75% and from 5 to 95% are approximately 11 and 28 minutes, respectively.</p><p style="margin-left:3.6pt; margin-right:0cm"><u>Reversal </u>&nbsp;</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">Neuromuscular block following cisatracurium administration is readily reversible with standard doses of anti-cholinesterase agents. The mean duration of recovery from 25 to 75% and to full clinical recovery (T4:T1 ratio&nbsp; 0.7) are approximately 2 and 5 minutes respectively, following administration of the reversal agent at an average T1 recovery of 13%.</p><p style="margin-left:3.6pt; margin-right:0cm"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use by intravenous infusion</strong></p><p style="margin-left:3.6pt; margin-right:0cm"><strong><em>Dosage in adults and children aged 2 to 12 years</em></strong></p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">Maintenance of neuromuscular block is achieved by infusion of Cis-Tac. Following evidence of spontaneous recovery, an initial infusion rate of 3 &mu;g/kg/min (0.18 mg/kg/h) is recommended to restore 89 to 99% T1 suppression. After a primary stabilisation period of the neuromuscular block, an infusion rate of 1 to 2 &mu;g/kg/min (0.06 to 0.12 mg/kg/h) should be adequate to maintain block in this range in most patients.</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">Reduction of the infusion rate by up to 40% may be required when cisatracurium is administered during isoflurane or enflurane anaesthesia (see section 4.5).</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">The infusion rate depends on the concentration of cisatracurium in the infusion solution, the desired degree of neuromuscular block, and the patient&#39;s body weight. The following table provides guidelines for infusion of undiluted Cis-Tac.</p><p style="margin-left:3.6pt; margin-right:0cm">Infusion Rate of Cis-Tac:</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="2" style="border-color:black; height:19.45pt; vertical-align:top; width:89.3pt"><p style="margin-left:1.8pt; margin-right:0cm">Patient (body weight) (kg)</p></td><td colspan="4" style="border-color:black; height:19.45pt; width:278.4pt"><p style="margin-left:3.1pt; margin-right:0cm">Dose (&micro;g/kg/min)</p></td><td rowspan="2" style="border-color:black; height:19.45pt; vertical-align:top; width:46.3pt"><p style="margin-left:1.8pt; margin-right:0cm">Infusion Rate</p></td></tr><tr><td colspan="4" style="height:19.2pt; width:278.4pt"><p style="margin-left:3.1pt; margin-right:0cm">1.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.0</p></td></tr><tr><td style="border-color:black; height:31.65pt; vertical-align:bottom; width:89.3pt"><p style="margin-left:3.35pt; margin-right:0cm">20</p></td><td style="height:31.65pt; vertical-align:bottom; width:72.0pt"><p style="margin-left:0cm; margin-right:0cm">0.6</p></td><td style="height:31.65pt; vertical-align:bottom; width:67.2pt"><p style="margin-left:0cm; margin-right:0cm">0.9</p></td><td style="height:31.65pt; vertical-align:bottom; width:72.0pt"><p style="margin-left:0cm; margin-right:0cm">1.2</p></td><td style="height:31.65pt; vertical-align:bottom; width:67.2pt"><p style="margin-left:0cm; margin-right:0cm">1.8</p></td><td style="height:31.65pt; vertical-align:bottom; width:46.3pt"><p style="margin-left:3.1pt; margin-right:0cm">ml/h</p></td></tr><tr><td style="border-color:black; height:19.2pt; width:89.3pt"><p style="margin-left:3.35pt; margin-right:0cm">70</p></td><td style="height:19.2pt; width:72.0pt"><p style="margin-left:0cm; margin-right:0cm">2.1</p></td><td style="height:19.2pt; width:67.2pt"><p style="margin-left:0cm; margin-right:0cm">3.2</p></td><td style="height:19.2pt; width:72.0pt"><p style="margin-left:0cm; margin-right:0cm">4.2</p></td><td style="height:19.2pt; width:67.2pt"><p style="margin-left:0cm; margin-right:0cm">6.3</p></td><td style="height:19.2pt; width:46.3pt"><p style="margin-left:3.1pt; margin-right:0cm">ml/h</p></td></tr><tr><td style="border-color:black; height:19.7pt; width:89.3pt"><p style="margin-left:3.35pt; margin-right:0cm">100</p></td><td style="height:19.7pt; width:72.0pt"><p style="margin-left:0cm; margin-right:0cm">3.0</p></td><td style="height:19.7pt; width:67.2pt"><p style="margin-left:0cm; margin-right:0cm">4.5</p></td><td style="height:19.7pt; width:72.0pt"><p style="margin-left:0cm; margin-right:0cm">6.0</p></td><td style="height:19.7pt; width:67.2pt"><p style="margin-left:0cm; margin-right:0cm">9.0</p></td><td style="height:19.7pt; width:46.3pt"><p style="margin-left:3.1pt; margin-right:0cm">ml/h</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">Steady rate continuous infusion is not associated with a progressive increase or decrease in neuromuscular blocking effect.</p><p style="margin-left:3.6pt; margin-right:7.2pt; text-align:justify">Following termination of infusion, spontaneous recovery from neuromuscular block proceeds at a rate comparable to that following administration of a single bolus injection.</p><p>&nbsp;</p><p style="margin-left:7.2pt; margin-right:82.8pt"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use by intravenous bolus injection and/or by intravenous infusion <em>Dosage in adults</em></strong></p><p style="margin-left:7.2pt; margin-right:1.8pt"><u>Intensive Care Unit (ICU) patients </u></p><p style="margin-left:7.2pt; margin-right:1.8pt">Cis-Tac may be administered by bolus dose and/or infusion to adult patients in the ICU.</p><p style="margin-left:7.2pt; margin-right:7.2pt; text-align:justify">An initial infusion rate of 3 &mu;g/kg/min (0.18 mg/kg/h) is recommended for adult ICU patients. There may be wide interpatient variation in dosage requirements and these may increase or decrease with time. In clinical studies the average infusion rate was 3 &mu;g/kg/min [range 0.5 to 10.2 &mu;g/kg (body weight)/min (0.03 to 0.6 mg/kg/h)].</p><p style="margin-left:7.2pt; margin-right:7.2pt; text-align:justify">The mean duration to full spontaneous recovery following long-term (up to 6 days) infusion of cisatracurium in ICU patients was approximately 50 minutes.</p><p style="margin-left:7.2pt; margin-right:7.2pt; text-align:justify">The recovery profile after infusions of cisatracurium to ICU patients is independent of the duration of the infusion.</p><p style="margin-left:7.2pt; margin-right:1.8pt"><strong>Special populations</strong></p><p style="margin-left:7.2pt; margin-right:1.8pt"><em>Dosage in elderly patients</em></p><p style="margin-left:7.2pt; margin-right:7.2pt; text-align:justify">No dosing alterations are required in elderly patients. In these patients a pharmacodynamic profile similar to young adult patients is observed but, as with other neuromuscular blocking agents, a delayed onset might occur.</p><p style="margin-left:7.2pt; margin-right:1.8pt"><em>Dosage in patients with renal impairment</em></p><p style="margin-left:7.2pt; margin-right:1.8pt">No dosing alterations are required in patients with renal failure.</p><p style="margin-left:7.2pt; margin-right:1.8pt">In these patients a similar pharmacodynamic profile to that in patients with normal renal</p><p style="margin-left:7.2pt; margin-right:1.8pt">function is observed but a delayed onset might occur.</p><p style="margin-left:7.2pt; margin-right:1.8pt"><em>Dosage in patients with hepatic impairment</em></p><p style="margin-left:7.2pt; margin-right:7.2pt; text-align:justify">No dosing alterations are required in patients with end-stage liver disease. In these patients a similar pharmacodynamic profile to that in patients with normal hepatic function is observed but a slightly accelerated onset might occur.</p><p style="margin-left:7.2pt; margin-right:1.8pt"><em>Dosage in patients with cardiovascular disease</em></p><p style="margin-left:7.2pt; margin-right:7.2pt; text-align:justify">When administered by rapid bolus injection (over 5 to 10 seconds) to adult patients with serious cardiovascular disease (New York Heart Association Class I-III) undergoing coronary artery bypass graft (CABG) surgery, cisatracurium has not been associated with clinically significant cardiovascular effects at any dose studied (maximal 0.4 mg/kg (8x ED95). However, there are limited data for doses above 0.3 mg/kg bw in this patient population.</p><p style="margin-left:7.2pt; margin-right:1.8pt">Cisatracurium has not been studied in children undergoing cardiac surgery.</p><p style="margin-left:7.2pt; margin-right:1.8pt"><strong><em>Paediatric population</em></strong></p><p style="margin-left:7.2pt; margin-right:1.8pt"><em>Dosage in new-born infants (aged less than 1 month)</em></p><p style="margin-left:7.2pt; margin-right:1.8pt">The use of cisatracurium in new-born infants is not recommended as it has not been studied in</p><p style="margin-left:7.2pt; margin-right:1.8pt">this patient population.</p><p style="margin-left:7.2pt; margin-right:1.8pt"><strong><u>Method of administration </u></strong></p><p style="margin-left:7.2pt; margin-right:1.8pt">Cis-Tac is for intravenous use</p><p style="margin-left:7.2pt; margin-right:1.8pt">Cis-Tac contains no antimicrobial preservative and is intended for single dose use only.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">The medicinal product should be visually inspected prior to use. The solution should only be used if it is clear and colourless or almost colourless up to slightly yellow/greenish yellow, practically free from particles and if the container is undamaged. If the visual appearance has changed or if the container is damaged, the product must be discarded.</p><p style="margin-left:36.0pt; margin-right:0cm">For instructions on dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to cisatracurium, atracurium or benzenesulfonic acid
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm"><em>Product specific topics</em></p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Cisatracurium paralyses the respiratory muscles as well as other skeletal muscles but has no known effect on consciousness or pain threshold.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Caution should be exercised when administering cisatracurium to patients who have shown hypersensitivity to other neuromuscular blocking agents since a high rate of cross-sensitivity (greater than 50%) between neuromuscular blocking agents has been reported.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Cisatracurium does not have significant vagolytic or ganglion- blocking properties. Consequently, cisatracurium has no clinically significant effect on heart rate and will not counteract the bradycardia produced by many anaesthetic agents or by vagal stimulation during surgery.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Patients with myasthenia gravis and other forms of neuromuscular disease have shown greatly increased sensitivity to non-depolarising blocking agents. An initial dose of not more than 0.02 mg/kg is recommended in these patients.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Severe acid-base and/or serum electrolyte abnormalities may increase or decrease the sensitivity of patients to neuromuscular blocking agents.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">There is no information on the use of cisatracurium in new-born infants aged less than one month since it has not been studied in this patient population.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Cisatracurium has not been studied in patients with a history of malignant hyperthermia. Studies in malignant hyperthermia- susceptible pigs indicated that cisatracurium does not trigger this syndrome.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">There have been no studies of cisatracurium in patients undergoing surgery with induced hypothermia (25 to 28&deg; C). The rate of infusion required to maintain adequate surgical relaxation under these conditions may be expected to be significantly reduced.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Cisatracurium has not been studied in patients with burns; however, the possibility of increased dosing requirements and shortened duration of action must be considered if cisatracurium is administered to these patients.</p><p style="margin-left:36.0pt; margin-right:0cm">Cis-Tac is hypotonic and must not be applied into the infusion line of a blood transfusion.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify"><em>Intensive Care Unit (ICU) Patients</em></p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">When administered to laboratory animals in high doses, laudanosine, a metabolite of cisatracurium and atracurium, has been associated with transient hypotension and in some species, cerebral excitatory effects. In the most sensitive animal species, these effects occurred at laudanosine plasma concentrations similar to those that have been observed in some ICU patients following prolonged infusion of atracurium.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Consistent with the decreased infusion rate requirements of cisatracurium, plasma laudanosine concentrations are approximately one third those following atracurium infusion.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">There have been rare reports of seizures in ICU patients who have received atracurium and other agents. These patients usually had one or more medical conditions predisposing to seizures (e.g. cranial trauma, hypoxic encephalopathy, cerebral oedema, viral encephalitis, uraemia). A causal relationship to laudanosine has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Many medicinal products have been shown to influence the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents, including the following:</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Increased Effect:</em></p><p style="margin-left:68.4pt; text-align:justify; text-indent:-18.0pt">-&nbsp;&nbsp;&nbsp;&nbsp; by anaesthetic medicinal products such as enflurane, isoflurane, halothane (see section 4.2) and ketamine,</p><p style="margin-left:50.4pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by other non-depolarising neuromuscular blocking agents,</p><p style="text-align:center">- by other medicinal products such as antibiotics (including the aminoglycosides, polymyxins, spectinomycin, tetracyclines, lincomycin and clindamycin),</p><p style="margin-left:50.4pt">- by antiarrhythmics(including propranolol, calcium channel blockers, lidocaine,</p><p style="margin-left:68.4pt">procainamide and quinidine),</p><p style="margin-left:50.4pt">- by diuretics, (including furosemide and possibly thiazides, mannitol and</p><p style="margin-left:68.4pt">acetazolamide),</p><p style="margin-left:50.4pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by magnesium and lithium salts and</p><p style="margin-left:50.4pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by ganglion blocking agents (trimetaphan, hexamethonium).</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Rarely, certain medicinal products may aggravate or unmask latent myasthenia gravis or actually induce a myasthenic syndrome; increased sensitivity to non-depolarising neuromuscular blocking agents might result. Such agents include various antibiotics, betablockers (propranolol, oxprenolol), antiarrhythmics (procainamide, quinidine), antirheumatics (chloroquine, D-penicillamine), trimetaphan, chlorpromazine, steroids, phenytoin and lithium.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Administration of suxamethonium to prolong the effects of non- depolarising neuromuscular blocking agents may result in a prolonged and complex block which can be difficult to reverse with anticholinesterases.</p><p style="margin-left:36.0pt; margin-right:0cm">Decreased effect</p><p style="margin-left:36.0pt; margin-right:0cm">A decreased effect is seen after preceding chronic administration of phenytoin or</p><p style="margin-left:36.0pt">carbamazepine.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Treatment with anticholinesterases, commonly used in the treatment of Alzheimer&#39;s disease e.g. donepezil, may shorten the duration and diminish the magnitude of neuromuscular blockade with cisatracurium.</p><p style="margin-left:36.0pt; margin-right:0cm">No effect:</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Preceding administration of suxamethonium has no effect on the duration of neuromuscular block following bolus doses of cisatracurium or on infusion rate requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm"><u>Pregnancy </u>&nbsp;</p><p style="margin-left:36.0pt; margin-right:0cm">There are no adequate data from the use of cisatracurium in pregnant women. Animal studies</p><p style="margin-left:36.0pt">are insufficient with respect to effects on pregnancy, embryonic/foetal development,</p><p style="margin-left:36.0pt; margin-right:0cm">parturition and postnatal development (see section 5.3). The potential risk for humans is</p><p style="margin-left:36.0pt">unknown.</p><p style="margin-left:36.0pt">Cis-Tac should not be used during pregnancy.</p><p style="margin-left:36.0pt; margin-right:0cm"><u>Breast-feeding</u></p><p style="margin-left:36.0pt; margin-right:7.2pt">It is not known whether cisatracurium or its metabolites are excreted in human milk. A risk to the breastfed infant cannot be excluded. Due to the short half-life, an influence on the breastfed infant is not to be expected if the mother restarts breast-feeding after the effects of the substance have worn off. As a precaution breast-feeding should be discontinued during treatment and for at least 12 hours after administration of Cis-Tac.</p><p style="margin-left:36.0pt; margin-right:0cm"><u>Fertility: </u></p><p style="margin-left:36.0pt; margin-right:0cm"><u>Fertility studies have not been performed</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:36.0pt">Cis-Tac as all other anaesthetics can have major influence on the ability to drive or use machines. The patient must not drive or operate machines following anaesthesia with cisatracurium.</p><p style="margin-left:36.0pt; margin-right:0cm">The time factor should be decided individually by the physician.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm">The frequency of undesirable effects is classified into the following categories:</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:13.45pt; width:85.2pt"><p style="margin-left:7.2pt">Very common</p></td><td style="border-color:black; height:13.45pt; width:276.0pt"><p style="margin-left:3.6pt">21/10</p></td></tr><tr><td style="border-color:black; height:12.95pt; width:85.2pt"><p style="margin-left:7.2pt">Common</p></td><td style="height:12.95pt; width:276.0pt"><p style="margin-left:3.6pt">21/100 to &lt;1/10</p></td></tr><tr><td style="border-color:black; height:13.2pt; width:85.2pt"><p style="margin-left:7.2pt">Uncommon</p></td><td style="height:13.2pt; width:276.0pt"><p style="margin-left:3.6pt">21/1,000 to &lt;1/100</p></td></tr><tr><td style="border-color:black; height:13.2pt; width:85.2pt"><p style="margin-left:7.2pt">Rare</p></td><td style="height:13.2pt; width:276.0pt"><p style="margin-left:3.6pt">21/10, 000 to &lt;1/1,000</p></td></tr><tr><td style="border-color:black; height:13.2pt; width:85.2pt"><p style="margin-left:7.2pt">Very rare</p></td><td style="height:13.2pt; width:276.0pt"><p style="margin-left:3.6pt">&lt;1/10, 000</p></td></tr><tr><td style="border-color:black; height:13.7pt; width:85.2pt"><p style="margin-left:7.2pt; margin-right:0cm">Not known</p></td><td style="height:13.7pt; width:276.0pt"><p style="margin-left:3.6pt; margin-right:0cm">cannot be estimated from the available data</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Immune system Disorders:</em></p><p style="margin-left:36.0pt; margin-right:0cm">Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic reactions</p><p style="margin-left:36.0pt; text-align:justify">Anaphylactic reactions of varying degrees of severity have been observed after the administration of neuromuscular blocking agents. Very rarely, severe anaphylactic reactions have been reported in patients receiving cisatracurium in conjunction with one or more anaesthetic agents.</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Cardiac Disorders:</em></p><p style="margin-left:36.0pt; margin-right:0cm">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bradycardia</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Vascular Disorders:</em></p><p style="margin-left:36.0pt; margin-right:0cm">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension</p><p style="margin-left:36.0pt">Uncommon: Cutaneous flushing</p><p style="margin-left:36.0pt; margin-right:194.4pt; text-align:justify"><em>Respiratory, Thoracic and Mediastinal Disorders: </em>Uncommon: Bronchospasm</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Skin and subcutaneous tissue Disorders: </em><br />Uncommon: Rash</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Musculoskeletal and connective Tissue Disorders:</em></p><p style="margin-left:36.0pt; margin-right:0cm">Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myopathy, muscle weakness</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">There have been some reports of muscle weakness and/or myopathy following prolonged use of muscle relaxants in severely ill patients in the ICU. Most patients were receiving concomitant corticosteroids. These events have been reported infrequently in association with cisatracurium and a causal relationship has not been established.</p><p style="margin-left:36.0pt; margin-right:0cm"><u>Reporting of suspected adverse reactions </u></p><p style="margin-left:36.0pt; margin-right:10.8pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below:</p><p style="margin-left:57.6pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong><em>Saudi Arabia:</em></strong></p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="border-color:black; height:89.5pt; vertical-align:top; width:391.95pt"><p style="margin-left:10.8pt; margin-right:0cm">The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="margin-left:32.4pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fax: +966-11-205-7662</p><p style="margin-left:32.4pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p style="margin-left:32.4pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->Toll free phone: 19999</p><p style="margin-left:32.4pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa<u> </u></p><p style="margin-left:32.4pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->Website:<u> </u>www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:57.6pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong><em>Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm"><em>Symptoms and signs</em></p><p style="margin-left:36.0pt; margin-right:0cm">Prolonged muscle paralysis and its consequences are expected to be the main signs of</p><p style="margin-left:36.0pt; margin-right:0cm">overdose with cisatracurium.</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Management</em></p><p style="margin-left:36.0pt; text-align:justify">It is essential to maintain pulmonary ventilation and arterial oxygenation until adequate spontaneous respiration returns. Full sedation will be required since consciousness is not impaired by cisatracurium. Recovery may be accelerated by the administration of anti-cholinesterase agents once evidence of spontaneous recovery is present.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm">Pharmacotherapeutic group: Muscle relaxants, peripherally acting agents; other quaternary</p><p style="margin-left:36.0pt; margin-right:0cm">ammonium compound,</p><p style="margin-left:36.0pt">ATC code: M03AC11</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Cisatracurium is an intermediate-duration, non-depolarising benzylisoquinolinium skeletal muscle relaxant.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Clinical studies in man indicated that cisatracurium is not associated with dose dependent histamine release even at doses up to and including 8 x ED95.</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Mechanism of action</em></p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Cisatracurium binds to cholinergic receptors on the motor end-plate to antagonise the action of acetylcholine, resulting in a competitive block of neuromuscular transmission. This action is readily reversed by anti-cholinesterase agents such as neostigmine or edrophonium.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">The ED95 (dose required to produce 95% depression of the twitch response of the adductor pollicis muscle to stimulation of the ulnar nerve) of cisatracurium is estimated to be 0.05 mg/kg bodyweight during opioid anaesthesia (thiopentone/fentanyl/midazolam).</p><p>The ED95 of cisatracurium in children during halothane anaesthesia is 0.04 mg/kg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm; text-align:justify"><em>Biotransformation/Elimination</em></p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Cisatracurium undergoes degradation in the body at physiological pH and temperature by Hofmann elimination (a chemical process) to form laudanosine and the monoquaternary acrylate metabolite. The monoquaternary acrylate undergoes hydrolysis by non-specific plasma esterases to form the monoquaternary alcohol metabolite. Elimination of cisatracurium is largely organ independent but the liver and kidneys are primary pathways for the clearance of its metabolites.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">These metabolites do not possess neuromuscular blocking activity.</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Pharmacokinetics in adult patients</em></p><p style="margin-left:36.0pt">Non-compartmental pharmacokinetics of cisatracurium are independent of dose in the range studied (0.1 to 0.2 mg/kg, i.e. 2 to 4 x ED95).</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Population pharmacokinetic modelling confirms and extends these findings up to 0.4 mg/kg (8 x ED95). Pharmacokinetic parameters after doses of 0.1 and 0.2 mg/kg cisatracurium administered to healthy adult surgical patients are summarised in the table below:</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:19.2pt; width:209.5pt"><p style="margin-left:3.35pt; margin-right:0cm">Parameter</p></td><td style="border-color:black; height:19.2pt; width:205.0pt"><p style="margin-left:3.15pt; margin-right:0cm">Range of Mean Values</p></td></tr><tr><td style="border-color:black; height:19.2pt; width:209.5pt"><p style="margin-left:3.35pt; margin-right:0cm">Clearance</p></td><td style="height:19.2pt; width:205.0pt"><p style="margin-left:3.15pt; margin-right:0cm">4.7 to 5.7 ml/min/kg</p></td></tr><tr><td style="border-color:black; height:19.2pt; width:209.5pt"><p style="margin-left:3.35pt; margin-right:0cm">Volume of distribution at steady state</p></td><td style="height:19.2pt; width:205.0pt"><p style="margin-left:3.15pt; margin-right:0cm">121 to 161 ml/kg</p></td></tr><tr><td style="border-color:black; height:19.7pt; width:209.5pt"><p style="margin-left:3.35pt; margin-right:0cm">Elimination half-life</p></td><td style="height:19.7pt; width:205.0pt"><p style="margin-left:3.15pt; margin-right:0cm">22 to 29 min</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Pharmacokinetics in elderly patients</em></p><p style="margin-left:36.0pt">There are no clinically important differences in the pharmacokinetics of cisatracurium in</p><p style="margin-left:36.0pt; margin-right:0cm">elderly and young adult patients. The recovery profile is also unchanged.</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Pharmacokinetics in patients with renal/hepatic impairment</em></p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">There are no clinically important differences in the pharmacokinetics of cisatracurium in patients with end-stage renal failure or end stage liver disease and in healthy adult patients. Their recovery profiles are also unchanged.</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Pharmacokinetics during infusions</em></p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">The pharmacokinetics of cisatracurium after infusions of cisatracurium are similar to those after single bolus injection. The recovery profile after infusion of cisatracurium is independent of duration of infusion and is similar to that after single bolus injection.</p><p style="margin-left:36.0pt; margin-right:0cm"><em>Pharmacokinetics in Intensive Care Unit (ICU) patients</em></p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">The pharmacokinetics of cisatracurium in ICU patients receiving prolonged infusions are similar to those in healthy surgical adults receiving infusions or single bolus injections. The recovery profile after infusions of cisatracurium in ICU patients is independent of duration of infusion.</p><p style="margin-left:36.0pt; margin-right:0cm">Concentrations of metabolites are higher in ICU patients with abnormal renal and/or hepatic</p><p style="margin-left:36.0pt; margin-right:0cm">function (see section 4.4). These metabolites do not contribute to neuromuscular block.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm">Cisatracurium was not mutagenic in an in vitro microbial mutagenicity test at concentrations up to 5000 &mu;g/plate.</p><p style="margin-left:36.0pt; margin-right:0cm">In an in vivo cytogenetic study in rats, no significant chromosomal abnormalities were seen at s.c. doses up to 4 mg/kg.</p><p style="margin-left:36.0pt; margin-right:0cm">Cisatracurium was mutagenic in an in vitro mouse lymphoma cell mutagenicity assay, at concentrations of 40 &mu;g/ml and higher.</p><p style="margin-left:36.0pt">A single positive mutagenic response for an active substance used infrequently and/or briefly is of questionable clinical relevance.</p><p style="margin-left:36.0pt; margin-right:0cm">Carcinogenicity studies have not been performed.</p><p style="margin-left:36.0pt; margin-right:0cm">Fertility studies have not been performed. Reproductive studies in rats have not revealed any adverse effects of cisatracurium on foetal development.</p><p style="margin-left:36.0pt; margin-right:0cm">The result of an intra-arterial local tolerance study in rabbits showed that cisatracurium injection is well tolerated and no drug related changes were seen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm">Benzenesulfonic acid 1% (for pH-adjustment)<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:39.6pt">This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p style="margin-left:36.0pt; margin-right:0cm">Since cisatracurium is stable only in acidic solutions it should not be mixed in the same syringe or administered simultaneously through the same needle with alkaline solutions, e.g., sodium thiopentone.</p><p style="margin-left:36.0pt; margin-right:0cm">It is not compatible with ketorolac trometamol or propofol injectable emulsion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened ampoule: 2 years
Shelf life after first opening:
The medicinal product should be used immediately after opening the ampoule.
Shelf life after dilution:
Chemical and physical in-use stability have been demonstrated for 24 hours at 25 °C.
From a microbiological point of view, the product should be used immediately. If not used
immediately, in-use storage times and conditions prior to use are the responsibility of the user
and would normally not be longer than 24 hours at 2-8°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm">Store in a refrigerator (2 &ndash; 8&deg;C).</p><p style="margin-left:36.0pt; margin-right:0cm">Do not freeze.</p><p style="margin-left:36.0pt; margin-right:0cm">Keep ampoules in the outer carton in order to protect from light.</p><p style="margin-left:36.0pt; margin-right:18.0pt">For storage conditions after dilution and first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:0cm">2.5 ml, 5 ml and 10 ml in colourless, type I glass ampoules</p><p style="margin-left:36.0pt; margin-right:0cm">Pack sizes:</p><p style="margin-left:36.0pt; margin-right:0cm">5 Ampoules X 2.5 ml</p><p style="margin-left:36.0pt; margin-right:0cm">5 Ampoules X 5 ml</p><p style="margin-left:36.0pt; margin-right:0cm">Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:36.0pt; margin-right:43.2pt">Any unused product or waste material should be disposed of in accordance with local requirements.</p><p style="margin-left:36.0pt; margin-right:3.6pt">Diluted to concentrations between 0.1 and 2 mg cisatracurium/ml Cis-Tac is physically and chemically stable for 24 hours at 5&ordm;C and 25&deg;C in Sodium Chloride 9 mg/ml (0.9% w/v) Intravenous Infusion, Glucose 50 mg/ml (5% w/v) Intravenous Infusion, Sodium Chloride 1.8 mg/ml (0.18% w/v) and Glucose 40 mg/ml (4% w/v) Intravenous Infusion, Sodium Chloride 4.5 mg/ml (0.45% w/v) and Glucose 25 mg/ml (2.5% w/v) Intravenous Infusion.</p><p style="margin-left:36.0pt; margin-right:0cm; text-align:justify">Cisatracurium has been shown to be compatible with the following commonly used peri-operative medicinal products, when mixed in conditions simulating administration into a running intravenous infusion via a Y-site injection port: alfentanil hydrochloride, droperidol, fentanyl citrate, midazolam hydrochloride and sufentanil citrate. Where other agents are administered through the same indwelling needle or cannula as cisatracurium, it is recommended that each medicinal product be flushed through with an adequate volume of a suitable intravenous fluid, e.g., sodium chloride 9 mg/ml (0.9%) solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fresenius Kabi Deutschland GmbH
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>